Research Analysts Set Expectations for DNLI FY2029 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Investment analysts at B. Riley issued their FY2029 earnings per share estimates for Denali Therapeutics in a research report issued on Wednesday, March 5th. B. Riley analyst M. Mamtani expects that the company will post earnings per share of $0.87 for the year. B. Riley currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08.

DNLI has been the subject of a number of other reports. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a report on Friday, February 28th. HC Wainwright raised their target price on shares of Denali Therapeutics from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Robert W. Baird started coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price objective for the company. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 7th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research note on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price objective for the company. Two analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $37.57.

Denali Therapeutics Stock Up 2.2 %

Shares of Denali Therapeutics stock opened at $16.30 on Thursday. The business has a fifty day simple moving average of $21.07 and a 200-day simple moving average of $24.46. Denali Therapeutics has a fifty-two week low of $14.01 and a fifty-two week high of $33.33. The firm has a market cap of $2.35 billion, a price-to-earnings ratio of -5.91 and a beta of 1.43.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Sterling Capital Management LLC boosted its stake in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after acquiring an additional 1,516 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Denali Therapeutics during the fourth quarter worth approximately $62,000. Point72 Hong Kong Ltd acquired a new position in Denali Therapeutics during the fourth quarter valued at approximately $65,000. Quest Partners LLC bought a new position in shares of Denali Therapeutics in the third quarter valued at approximately $73,000. Finally, PNC Financial Services Group Inc. raised its position in shares of Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after purchasing an additional 885 shares during the period. 92.92% of the stock is currently owned by institutional investors.

Insider Transactions at Denali Therapeutics

In related news, Director Vicki L. Sato sold 3,080 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the transaction, the director now owns 107,976 shares in the company, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the sale, the chief executive officer now owns 260,721 shares of the company’s stock, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,940 shares of company stock valued at $973,442 in the last three months. Corporate insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.